Sun Pharma to introduce complete range of Brivaracetam

23 Feb 2021

Sun Pharmaceutical Industries is going to introduce the complete range of Brivaracetam dosage forms at an affordable price for epilepsy treatment in India. Sun Pharma’s brand, Brevipil (Brivaracetam) tablet 25 mg/50 mg/75 mg/100 mg was launched in the market on Day-1 post patent expiry of innovator product (February 21, 2021). Brevipil oral solution (10 mg/ml) and injectable (10 mg/ml) will be available in the market over the next few weeks. Brivaracetam is approved by the Drugs Controller General of India (DCGI), as an adjunctive therapy in treatment of partial-onset seizures in patients 16 years of age and older with epilepsy.

Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.

Related Sun Pharmaceutical Industries Ltd. Links:

Sun Pharma Inds. Share Price

614.85 3.90 (0.64%) Mar 08, 18:37
1 Year Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 614.85
Dr. Reddys Lab 4490.20
Lupin 1050.45
Piramal Enterprises 1917.10
Cadila Healthcare 446.10
View more..
Sensex vs Sun Pharma Inds.
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback